TABLE 1.
The relationship between AAPR tertile and clinicopathological parameters in the present advanced NSCLC cohort (n = 808)
| AAPR Tertile | Total | Low | Medium | High | P‐value |
|---|---|---|---|---|---|
| Number of patients | 808 | 266 | 259 | 283 | |
| Age | 58.32 ± 10.88 | 57.91 ± 9.73 | 59.47 ± 10.68 | 57.67 ± 11.97 | .117 |
| Age | .076 | ||||
| <65 | 577 (71.41%) | 203 (76.60%) | 177 (68.34%) | 197 (69.61%) | |
| ≥65 | 231 (28.59%) | 62 (23.40%) | 82 (31.66%) | 86 (30.39%) | |
| Gender | <.001 | ||||
| Male | 556 (68.64%) | 193 (72.56%) | 193 (74.52%) | 170 (60.07%) | |
| Female | 254 (31.36%) | 73 (27.44%) | 66 (25.48%) | 113 (39.93%) | |
| Smoking history | .061 | ||||
| Never | 385 (47.59%) | 119 (44.74%) | 110 (42.64%) | 154 (54.42%) | |
| Ever | 413 (51.05%) | 144 (54.14%) | 144 (55.81%) | 125 (44.17%) | |
| Unknown | 11 (1.36%) | 3 (1.13%) | 4 (1.55%) | 4 (1.41%) | |
| ECOG | .023 | ||||
| 0‐1 | 655 (87.45%) | 202 (82.79%) | 213 (89.87%) | 239 (89.85%) | |
| ≥2 | 94 (12.55%) | 42 (17.21%) | 24 (10.13%) | 27 (10.15%) | |
| Pathology | .090 | ||||
| Adenocarcinoma | 593 (73.21%) | 211 (79.32%) | 178 (68.73%) | 203 (71.73%) | |
| Squamous cell carcinoma | 190 (23.46%) | 48 (18.05%) | 71 (27.41%) | 70 (24.73%) | |
| Others | 27 (3.33%) | 7 (2.63%) | 10 (3.86%) | 10 (3.53%) | |
| Clinical stage | <.001 | ||||
| IIIA + IIIB | 120 (14.81%) | 20 (7.52%) | 49 (18.92%) | 51 (18.02%) | |
| IV | 690 (85.19%) | 246 (92.48%) | 210 (81.08%) | 232 (81.98%) | |
| Bone | <.001 | ||||
| No | 506 (64.05%) | 117 (44.15%) | 177 (68.87%) | 210 (78.95%) | |
| Yes | 284 (35.95%) | 148 (55.85%) | 80 (31.13%) | 56 (21.05%) | |
| Liver | <.001 | ||||
| No | 673 (85.19%) | 202 (76.23%) | 236 (91.83%) | 234 (87.97%) | |
| Yes | 117 (14.81%) | 63 (23.77%) | 21 (8.17%) | 32 (12.03%) | |
| Lung | .578 | ||||
| No | 489 (61.90%) | 168 (63.40%) | 162 (63.04%) | 158 (59.40%) | |
| Yes | 301 (38.10%) | 97 (36.60%) | 95 (36.96%) | 108 (40.60%) | |
| Brain | .234 | ||||
| No | 646 (81.77%) | 209 (78.87%) | 210 (81.71%) | 225 (84.59%) | |
| Yes | 144 (18.23%) | 56 (21.13%) | 47 (18.29%) | 41 (15.41%) | |
| Pleural effusion | .581 | ||||
| No | 491 (62.15%) | 170 (64.15%) | 160 (62.26%) | 159 (59.77%) | |
| Yes | 299 (37.85%) | 95 (35.85%) | 97 (37.74%) | 107 (40.23%) | |
| Number of organ metastasis | <.001 | ||||
| ≤3 | 429 (54.30%) | 110 (41.51%) | 140 (54.47%) | 178 (66.92%) | |
| >3 | 361 (45.70%) | 155 (58.49%) | 117 (45.53%) | 88 (33.08%) | |
| EGFR mutation | .183 | ||||
| Negative | 205 (25.31%) | 74 (27.82%) | 66 (25.48%) | 64 (22.61%) | |
| Positive | 137 (16.91%) | 53 (19.92%) | 42 (16.22%) | 42 (14.84%) | |
| Unknown | 468 (57.78%) | 139 (52.26%) | 151 (58.30%) | 177 (62.54%) | |
| ALK rearrangement | .001 | ||||
| Negative | 300 (37.04%) | 115 (43.23%) | 96 (37.07%) | 88 (31.10%) | |
| Positive | 29 (3.58%) | 16 (6.02%) | 7 (2.70%) | 6 (2.12%) | |
| Unknown | 481 (59.38%) | 135 (50.75%) | 156 (60.23%) | 189 (66.78%) | |
| First‐line regiment | .461 | ||||
| Platinum‐based doublet chemotherapy | 411 (65.24%) | 129 (63.55%) | 127 (65.46%) | 153 (66.23%) | |
| Single drug chemotherapy | 36 (5.71%) | 9 (4.43%) | 16 (8.25%) | 11 (4.76%) | |
| Targeted therapy | 125 (19.84%) | 49 (24.14%) | 33 (17.01%) | 43 (18.61%) | |
| Platinum‐based doublet chemotherapy plus angiogenesis‐therapy | 49 (7.78%) | 14 (6.90%) | 14 (7.22%) | 21 (9.09%) | |
| Others | 9 (1.43%) | 2 (0.99%) | 4 (2.06%) | 3 (1.30%) | |
| Number of treatment lines | .811 | ||||
| ≤3 | 489 (76.89%) | 161 (78.54%) | 150 (76.14%) | 177 (76.29%) | |
| >3 | 147 (23.11%) | 44 (21.46%) | 47 (23.86%) | 55 (23.71%) |
Abbreviations: AAPR, albumin‐to‐alkaline phosphatase ratio; ALK, anaplastic lymphoma kinase; ECOG‐PS, performance status of East Cooperative Oncology Group; EGFR, epidermal growth factor receptor; NSCLC, non‐small cell lung cancer.